We are excited to announce that one of the companies in our investment portfolio has successfully completed a new financing round. Genoa Pharmaceuticals, Inc., a privately held Seattle/San Diego-based pharmaceutical company developing next generation therapies for the treatment of Idiopathic Pulmonary Fibrosis, has raised $62 million in a Series A financing. The capital will be used to advance their lead asset, Aerodone™ for IPF through to Phase 2 proof-of-concept studies and will also support the development of additional assets within their pipeline towards clinical trials.

Aerodone™ is a unique reformulation of the FDA approved product Pirfenidone (Esbriet™) that is expected to improve its safety profile and enhance peripheral lung deposition in IPF patients, thereby increasing its efficacy.

genoa_pharmaceuticals_logo_insymbiosis

If you wish to learn more about Genoa Pharmaceuticals, please visit their website: www.genoapharma.com

The InSymbiosis Team